Exozymes grants director Rayo 25,000 stock options
The options vest over twelve quarterly installments through September 30, 2029, subject to the director's continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Exozymes Inc. director Edgardo Javier Rayo received a grant of 25,000 stock options on October 1, 2026, with an exercise price of $6.28 per share and an expiration date of October 1, 2033. The options vest in twelve quarterly installments: eleven installments of 2,083 shares and a final installment of 2,087 shares, beginning December 31, 2026 and ending September 30, 2029, subject to his continued service. The report also lists his direct ownership of 77,909 common shares on October 1, 2026.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 25,000 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. The option vests in twelve (12) quarterly installments, consisting of eleven (11) installments of 2,083 shares and a final installment of 2,087 shares, beginning on 12/31/2026 and ending on 09/30/2029, subject to the reporting person's continued service with the issuer. The option expires on 10/01/2033.
Key Figures
Key Terms
Stock Option (right to buy) financial
exercise price financial
vests financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What options did EXOZ director Edgardo Javier Rayo receive?
How do Edgardo Javier Rayo's EXOZ options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.